During the six months ended December 31, 2010, the Company generated cash from operations of $9.4 million and, at December 31, 2010, had $42.8 million of cash and investment balances and total debt of $30.7 million. In January 2011, the Company acquired the net assets of Nerites Corporation, a developer of medical adhesives and anti-fouling coatings for $20 million in cash, of which $17 million was paid at closing with the remainder expected to be paid over the next two years.
Fiscal 2011 GuidanceThe Company currently expects total revenues for fiscal year 2011 will be in the range of $73.0 to $75.0 million. Net sales and royalties are currently expected to be in the ranges of $46.7 to $48.3 million and $26.3 to $26.6 million, respectively. The Company had previously included approximately $1.5 million of endovascular milestone revenue in its guidance but has eliminated this from its current guidance due to the uncertainty of receiving these payments from Spectranectics.
The Company currently expects diluted earnings per share for fiscal 2011 will be in the range of $1.70 to $1.75 (excluding any in-process R&D charges and acquisition costs related to Nerites).
Fiscal 2011 will include a significant investment in research and development, with total research and development spending for fiscal 2011 estimated to be approximately $17 to $18 million. The Company plans to increase its clinical activities for the ECM products in the
|SOURCE Kensey Nash Corporation|
Copyright©2010 PR Newswire.
All rights reserved